26 Towards an HIV functional cure with CAR-T cells: elucidating mechanisms underlying the extremely high potency of bispecific anti-HIV CARs designed for optimal activity and minimal immunogenicity

• M.H. Ghanem,
• B. Dey,
• S. Bolivar-Wagers,
• D. Vargas-Inchaustegui,
• V. Bundoc,
• D.T. Danielson,
• D. Elias,
• A. Hajduczki,
• E.A. Berger

Affiliations

M.H. Ghanem

Molecular Structure Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, Maryland, USA

B. Dey

Molecular Structure Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, Maryland, USA

S. Bolivar-Wagers

Molecular Structure Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, Maryland, USA

D. Vargas-Inchaustegui

Molecular Structure Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, Maryland, USA

V. Bundoc

Molecular Structure Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, Maryland, USA

D.T. Danielson

Molecular Structure Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, Maryland, USA

D. Elias

Molecular Structure Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, Maryland, USA

A. Hajduczki

Molecular Structure Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, Maryland, USA

E.A. Berger

Molecular Structure Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, Maryland, USA